Compare SIRI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIRI | CYTK |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.7B |
| IPO Year | 1996 | 2004 |
| Metric | SIRI | CYTK |
|---|---|---|
| Price | $26.89 | $62.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 23 |
| Target Price | $33.23 | ★ $109.40 |
| AVG Volume (30 Days) | ★ 4.2M | 1.9M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 136.32 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $5,425,129,000.00 | $13,368,000.00 |
| Revenue This Year | $0.39 | $72.63 |
| Revenue Next Year | $1.41 | $181.06 |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 8.13 | N/A |
| 52 Week Low | $19.77 | $54.30 |
| 52 Week High | $32.66 | $88.31 |
| Indicator | SIRI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 39.59 |
| Support Level | $26.46 | $59.21 |
| Resistance Level | $27.80 | $67.65 |
| Average True Range (ATR) | 0.59 | 1.96 |
| MACD | 0.19 | 0.33 |
| Stochastic Oscillator | 58.92 | 40.35 |
Sirius XM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.